My Take: NWSA shares have struggled lately, but today's report shows they're not down and out just yet. Its current price could be a promising entry point for a potential swing trade.
Blue Bird [BLBD] - Last Close: $19.32
Another late-Thursday earnings beat is lifting shares of Blue Bird.
The school bus manufacturer reported fiscal Q2 results that beat the market's expectations for both earnings and revenues by substantial margins.
Bluebird generated fiscal Q2 EPS of $0.27 per share after posting a $(0.31) per share loss a year ago. Analysts expected EPS of $0.08.
Revenues grew 44.3% YoY to $299.8 million for the quarter, which beat the consensus of $249.5 million by more than 20%.
The company's full-year 2023 revenue guidance of just over $1.1 billion also surpassed analysts' $1.02 billion expectation.
BLBD is one of this morning's top premarket stocks with a 31.9% gain.
My Take: BLBD is doing great while many other businesses are struggling. The firm's past-year performance demonstrates that its business model could be particularly resistant to worsening economic conditions.
ARS Pharmaceuticals [SPRY] - Last Close: $4.52
A regulatory approval is giving ARS Pharma a premarket boost.
Late Thursday, the biopharma firm said the FDA's Pulmonary-Allergy Drug Advisory board voted in favor of its treatment for severe allergic reactions.
The panel voted that the available data supported a favorable risk-benefit assessment for ARS' allergy drug, neffy.
The vote supported neffy's approval as a treatment for severe allergic reaction, including anaphylaxis. for both adults and children.
Although the panel's vote is non-binding, it's much more likely that the FDA will approve ARS Pharma's new drug application for Neffy, which is sitll under review.
The FDA expects to make a decision by 2023. If approved, Neffy would become the first non-injectable treatment for patients with severe allergic reactions.
SPRY is up 64.8% on elevated trading volume in today's premarket.
My Take: SPRY's allergy drug appears to be on course for a full approval later in the year. The stock has experienced steep declines lately, but this could be the beginning of a rebound rally. This could be a promising biotech to watch.
Getaround [GETR] - Last Close: $0.3311
Shares of Getaround are surging after an acquisition announcement.
Late Thursday, the car sharing marketplace app announced it had acquired all assets of HyreCar [HYRE] in a $9.45 million deal.
The acquisition is expected to add up $75 million to Getaround's gross booking value and contribute positively to EBITDA.
Getaround said the deal will accelerate its path to profitability.
GETR is one of today's top premarket stocks with a 98.1% gain on elevated trading volume.
My Take: The market appears to really like this move,but GETR still has plenty of issues. I'm not sold just yet, but this deal seems to be a step in the right direction for the struggling car-share stock.
